We follow a large cohort of patients with inherited spinocerebellar ataxia, about half of whom have no known basis for their disease. In addition, we and our clinical colleagues, Susan Perlman and Joanna Jen continue to see ataxia patients in the neurology clinic and are working on national collaborative efforts to identify potential therapies and advance clinical trials in this area. We have used microarrays to study a Friedreich’s Ataxia mouse model and patient fibroblasts and have recently made significant progress (Coppola et al. 2006). We are moving to creating in vitro models for rapid drug screening so as to identify new targets for the disease (Giovanni Coppola and Maren Engelhardt) and develop biomarkers that can be used to track disease progress and treatment






The largest collection of well-characterized families with autism and related disorders is publicly available for any qualified researcher to use and study. This includes cell lines and an on-line phenotypic database. For more information see 

A collaborative effort between the Geschwind and Kornblum laboratories at UCLA. We used RDA and microarray technology to identify genes enriched in neural stem cell cultures, called neurospheres. This project is a first in this rapidly moving area and laid the groundwork for understanding the genetic basis of neural stem cell proliferation. A significant number of the genes enriched in neurospheres were also enriched in hematapoietic stem cells relative to whole bone marrow, suggesting a common genetic program (